Implementing a Pragmatic Clinical Trial to Tailor Opioids for Acute Pain on behalf of the IGNITE ADOPT PGx Investigators

Posted on by Mia
Larisa H Cavallari, Emily Cicali, Kristin Wiisanen, Roger B Fillingim, Hrishikesh Chakraborty, Rachel A Myers, Kathryn V Blake, Bolanle Asiyanbola, Jordan F Baye, Wesley H Bronson, Kelsey J Cook, Erica N Elwood, Chancellor F Gray, Yan Gong, Lindsay Hines, Joseph Kannry, Natalie Kucher, Sheryl Lynch, Khoa A Nguyen, Aniwaa Owusu Obeng, Victoria M Pratt, Hernan A Prieto, Michelle Ramos, Azita Sadeghpour, Rajbir Singh, Marc Rosenman, Petr Starostik, Cameron D Thomas, Emma Tillman, Paul R Dexter, Carol R Horowitz, Lori A Orlando, Josh F Peterson, Todd C Skaar, Sara L Van Driest, Simona Volpi, Deepak Voora, Hari K Parvataneni, Julie A Johnson, The IGNITE Pragmatic Trials Network

Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study

Posted on by Mia
Liewei Wang 1, Steven E Scherer 2, Suzette J Bielinski 3, Donna M Muzny 4, Leila A Jones 5, John Logan Black 3rd 6, Ann M Moyer 6, Jyothsna Giri 5, Richard R Sharp 7, Eric T Matey 8, Jessica A Wright 8, Lance J Oyen 8, Wayne T Nicholson 9, Mathieu Wiepert 10, Terri Sullard 5, Timothy B Curry 11, Carolyn R Rohrer Vitek 5, Tammy M McAllister 5, Jennifer L St Sauver 12, Pedro J Caraballo 13, Konstantinos N Lazaridis 14, Eric Venner 4, Xiang Qin 15, Jianhong Hu 4, Christie L Kovar 4, Viktoriya Korchina 4, Kimberly Walker 4, HarshaVardhan Doddapaneni 15, Tsung-Jung Wu 4, Ritika Raj 4, Shawn Denson 4, Wen Liu 4, Gauthami Chandanavelli 4, Lan Zhang 4, Qiaoyan Wang 15, Divya Kalra 15, Mary Beth Karow 6, Kimberley J Harris 6, Hugues Sicotte 6, Sandra E Peterson 6, Amy E Barthel 6, Brenda E Moore 6, Jennifer M Skierka 6, Michelle L Kluge 6, Katrina E Kotzer 6, Karen Kloke 6, Jessica M Vander Pol 6, Heather Marker 5, Joseph A Sutton 10, Adrijana Kekic 16, Ashley Ebenhoh 8, Dennis M Bierle 13, Michael J Schuh 17, Christopher Grilli 16, Sara Erickson 18, Audrey Umbreit 19, Leah Ward 17, Sheena Crosby 17, Eric A Nelson 16, Sharon Levey 20, Michelle Elliott 21, Steve G Peters 22, Naveen Pereira 23, Mark Frye 24, Fadi Shamoun 25, Matthew P Goetz 26, Iftikhar J Kullo 23, Robert Wermers 27, Jan A Anderson 8, Christine M Formea 8, Razan M El Melik 8, John D Zeuli 8, Joseph R Herges 8, Carrie A Krieger 8, Robert W Hoel 8, Jodi L Taraba 8, Scott R St Thomas 5, Imad Absah 28, Matthew E Bernard 29, Stephanie R Fink 30, Andrea Gossard 31, Pamela L Grubbs 32, Therese M Jacobson 32, Paul Takahashi 30, Sharon C Zehe 33, Susan Buckles 34, Michelle Bumgardner 32, Colette Gallagher 34, Kelliann Fee-Schroeder 5, Nichole R Nicholas 5, Melody L Powers 35, Ahmed K Ragab 5, Darcy M Richardson 5, Anthony Stai 10, Jaymi Wilson 5, Joel E Pacyna 7, Janet E Olson 36, Erica J Sutton 7, Annika T Beck 7, Caroline Horrow 7, Krishna R Kalari 37, Nicholas B Larson 37, Hongfang Liu 38, Liwei Wang 38, Guilherme S Lopes 39, Bijan J Borah 40, Robert R Freimuth 38, Ye Zhu 41, Debra J Jacobson 37, Matthew A Hathcock 37, Sebastian M Armasu 37, Michaela E McGree 37, Ruoxiang Jiang 37, Tyler H Koep 42, Jason L Ross 42, Matthew G Hilden 42, Kathleen Bosse 42, Bronwyn Ramey 42, Isabelle Searcy 42, Eric Boerwinkle 43, Richard A Gibbs 44, Richard M Weinshilboum 45
Affiliations

Medication exposure patterns in primary care patients prescribed pharmacogenetically actionable opioids

Posted on by Mia

Qualitative Report – This study’s purpose was to develop a typology of subgroups of patients who share common patterns of medication exposure. To create the typology, we used an exemplar sample of 30 patients in a large public healthcare system who had been prescribed the pharmacogenetically actionable opioids codeine or tramadol.

Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey

Posted on by Mia

Journal of Personalized Medicine – To understand potential barriers and provider attitudes, we surveyed 285 physicians from five Implementing GeNomics In pracTicE (IGNITE) sites about their perceptions as to the clinical utility of genetic data as well as their preparedness to integrate it into practice.

Role of genetic testing in patients undergoing percutaneous coronary intervention

Posted on by Mia

Expert Review of Clinical Pharmacology – The present manuscript provides an overview of genetic factors associated with response profiles to platelet P2Y12 receptor inhibitors and their clinical implications, as well as the most recent developments and future considerations on the role of genetic testing in patients undergoing PCI.